Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent Glioblastoma, IDH-Wildtype · Recurrent WHO Grade 2 Glioma · Recurrent WHO Grade 3 Glioma · Recurrent WHO Grade 4 Glioma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Northwestern University, Chicago, Illinois, United States
Contact: Study coordinator (Karan Dixit) · karan.dixit@northwetstern.edu · 312-503-1818
Contact: Principal Investigator (Karan Dixit)

Study leads

Karan Dixit, MD
Principal Investigator
Northwestern University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Recurrent Glioblastoma · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Relapsed Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2 · Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant · Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant

Abroad (travel likely)RecruitingPHASE1

Duarte, United States · Irvine, United States

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recurrent Astrocytoma, IDH-Mutant, Grade 4 · Recurrent Glioblastoma, IDH-Wildtype

Abroad (travel likely)RecruitingPHASE1

Duarte, United States

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Glioblastoma · Glioblastoma, IDH-Wildtype · Gliosarcoma

Abroad (travel likely)RecruitingPHASE1

Los Angeles, United States · New York, United States